BioInvent International AB (LTS:0H22) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BioInvent International AB EBITDA Margin % Related Terms
BioInvent International AB EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0H22 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, BioInvent International AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB (LTS:0H22) has a EBITDA Margin % of -870.86% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #550 out of 944 companies in the Biotechnology industry, placing it in the top 58.3%.
Is BioInvent International AB's EBITDA Margin % too high?
BioInvent International AB's current EBITDA Margin % is -870.86%. Based on the distribution chart, BioInvent International AB ranks #550 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #550 out of 944 companies for EBITDA Margin %. This places BioInvent International AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current EBITDA Margin % is -870.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
Based on GuruFocus' analysis, BioInvent International AB (LTS:0H22) is currently considered Possible Value Trap. The stock's GF Value™ is kr48.64, compared to a current price of kr23.63 — trading 51.4% below its estimated fair value. The current EBITDA Margin % is -870.86%. BioInvent International AB's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BioInvent International AB (LTS:0H22), the current EBITDA Margin % is -870.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (LTS:0H22) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of kr23.63 is trading 51.4% below its estimated GF Value™ of kr48.64.
GuruFocus considers BioInvent International AB to be Possible Value Trap.
Key valuation signals for LTS:0H22:
EBITDA Margin %: -870.86%
GF Value™: kr48.64 vs. price of kr23.63 (51.4% below fair value)
No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
48GF Score
Get the complete analysis for LTS:0H22
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H22 has been successfully added to your 
